119 related articles for article (PubMed ID: 2896204)
1. Hemodynamic effects of flestolol, a titratable short-acting intravenous beta-adrenergic receptor blocker.
Strom J; Josephson M; Frishman WH; Singh B; Heilbrunn S; Osterle S; Turlapaty P; Viray R; Coe J; Bell V
J Clin Pharmacol; 1988 Mar; 28(3):276-82. PubMed ID: 2896204
[TBL] [Abstract][Full Text] [Related]
2. Flestolol: an ultra-short-acting beta-adrenergic blocking agent.
Barton SD; Burge J; Turlapaty P; Laddu AR
J Clin Pharmacol; 1986 Mar; 26(S1):A36-A39. PubMed ID: 2870085
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of flestolol, a new short-acting, beta-adrenergic receptor antagonist.
Achari R; Drissel D; Hulse JD; Bell V; Turlapaty P; Laddu A; Matier WL
J Clin Pharmacol; 1987 Jan; 27(1):60-4. PubMed ID: 2890664
[TBL] [Abstract][Full Text] [Related]
4. Effects of flestolol, an ultra-short acting beta-adrenoceptor antagonist, on hemodynamic changes produced by treadmill exercise or isoprenaline stimulation in conscious dogs.
Grohs JG; Fischer G; Raberger G
J Cardiovasc Pharmacol; 1990 Feb; 15(2):175-81. PubMed ID: 1689410
[TBL] [Abstract][Full Text] [Related]
5. Hemodynamic effects of esmolol, an ultrashort-acting beta blocker.
Askenazi J; MacCosbe PE; Hoff J; Turlapaty P; Hua TA; Laddu A
J Clin Pharmacol; 1987 Aug; 27(8):567-73. PubMed ID: 2888793
[TBL] [Abstract][Full Text] [Related]
6. Tolerance and beta-adrenergic blocking activity of flestolol, a short-acting beta blocker.
Turlapaty P; Burge J; Hulse J; Achari R; Bell V; Mosberg H; Laddu A
Clin Pharmacol Ther; 1986 May; 39(5):543-9. PubMed ID: 3698462
[TBL] [Abstract][Full Text] [Related]
7. Controlled beta-receptor blockade with flestolol: a novel ultrashort-acting beta-blocker.
Murthy VS; Hwang TF; Rosen LB; Gorczynski RJ
J Cardiovasc Pharmacol; 1987 Jan; 9(1):72-8. PubMed ID: 2434798
[TBL] [Abstract][Full Text] [Related]
8. Antiarrhythmic activity of flestolol, a novel ultra-short-acting beta-adrenoceptor antagonist, in the dog.
Reynolds RD; Brown BS
Eur J Pharmacol; 1986 Nov; 131(1):55-66. PubMed ID: 2880726
[TBL] [Abstract][Full Text] [Related]
9. Controlled beta-receptor blockade with esmolol and flestolol.
Murthy VS; Frishman WH
Pharmacotherapy; 1988; 8(3):168-82. PubMed ID: 2902602
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of flestolol, a new ultrashort-acting beta-adrenergic blocking agent, for supraventricular tachyarrhythmias.
Steinberg JS; Katz RJ; Somberg JC; Keefe D; Laddu AR; Burge J
Am J Cardiol; 1986 Nov; 58(10):1005-8. PubMed ID: 2877563
[TBL] [Abstract][Full Text] [Related]
11. Clinical electrophysiology of flestolol, a potent ultra short-acting beta blocker.
Swerdlow CD; Peterson J; Turlapaty P
Am Heart J; 1986 Jan; 111(1):49-53. PubMed ID: 2868646
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of flestolol in man: preliminary data.
Achari R; Hulse JD; Drissel D; Matier WL
Br J Clin Pharmacol; 1985 Dec; 20(6):691-4. PubMed ID: 2868745
[TBL] [Abstract][Full Text] [Related]
13. Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings.
Turlapaty P; Laddu A; Murthy VS; Singh B; Lee R
Am Heart J; 1987 Oct; 114(4 Pt 1):866-85. PubMed ID: 2889341
[TBL] [Abstract][Full Text] [Related]
14. Verification of a canine model of transient exercise induced myocardial dysfunction: antianginal effects of flestolol, an ultra short acting beta adrenoceptor antagonist.
Fischer G; Grohs JG; Raberger G
Cardiovasc Res; 1990 Feb; 24(2):115-20. PubMed ID: 1970278
[TBL] [Abstract][Full Text] [Related]
15. Effect of flestolol on ventricular rate during atrial fibrillation in Wolff-Parkinson-White syndrome.
Swerdlow CD; Peterson J; Liem LB
Am J Cardiol; 1988 Jul; 62(1):78-82. PubMed ID: 2898208
[TBL] [Abstract][Full Text] [Related]
16. Quantitation of the ultra short acting beta-adrenergic antagonist flestolol in blood by liquid chromatography.
Moore P; Mai K; Lai CM
J Pharm Sci; 1986 Apr; 75(4):424-6. PubMed ID: 2873234
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular pharmacology of ACC-9089--a novel, ultra-short-acting, beta-adrenergic receptor antagonist.
Gorczynski RJ; Vuong A
J Cardiovasc Pharmacol; 1984; 6(4):555-64. PubMed ID: 6206307
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia.
Sung RJ; Blanski L; Kirshenbaum J; MacCosbe P; Turlapaty P; Laddu AR
J Clin Pharmacol; 1986 Mar; 26(S1):A15-A26. PubMed ID: 2870082
[TBL] [Abstract][Full Text] [Related]
19. Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent.
Angaran DM; Schultz NJ; Tschida VH
Clin Pharm; 1986 Apr; 5(4):288-303. PubMed ID: 2871961
[TBL] [Abstract][Full Text] [Related]
20. Beta-blocking and hemodynamic effects of ASL-8052.
Gorczynski RJ; Murthy VS; Hwang TF
J Cardiovasc Pharmacol; 1984; 6(6):1548-59. PubMed ID: 6084788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
